Hainan Simcere

Simcere Pharmaceutical Group is a leading innovation-driven pharmaceutical company in China, focusing on oncology, central nervous system diseases, and autoimmune disorders. The company maintains a robust R&D presence with multiple state-of-the-art facilities and a diverse portfolio of marketed products, including the first-in-class stroke treatment Sanbexin. Simcere has transitioned from a generic-heavy manufacturer to an innovation-led biotech player, leveraging internal R&D and global partnerships to develop small molecules and biologics. Their commercial operations are supported by extensive manufacturing capabilities in Nanjing and Hainan, catering to both domestic and international markets.